Business Context and Reporting Period
This Form 8-K was filed by Stereotaxis, Inc. on October 13, 2005, reporting an event that occurred on October 12, 2005. The filing concerns the company's strategic alliance with Biosense Webster, Inc., a Johnson & Johnson company, regarding the integration of new FDA-cleared devices with Stereotaxis' NIOBE Magnetic Navigation System.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a regulatory milestone and product integration rather than financial performance.
Material Changes
The material change reported is the FDA clearance of three Biosense Webster products designed to integrate with Stereotaxis' NIOBE system:
- CARTO RMT Navigation System
- NAVISTAR RMT Steerable Tip Diagnostic Catheter
- REFSTAR RMT Catheter with the QWIKPATCH External Reference Patch
These products are the first to be commercialized in the United States under the strategic alliance between Stereotaxis and Biosense. They provide electrophysiologists with additional tools for remote catheter steering but are not ablation catheters.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, outlook projections, or a discussion of risks and contingencies. Management commentary is limited to the announcement that the FDA clearance provides doctors with enhanced maneuvering capabilities when using the NIOBE Magnetic Navigation System.
Investor Verification Points
- Verify the commercial launch timeline for the newly cleared Biosense Webster products in the U.S. market.
- Confirm the specific revenue-sharing or royalty terms of the strategic alliance between Stereotaxis and Biosense Webster.
- Assess the competitive impact of these non-ablation diagnostic tools on Stereotaxis' overall market position.